Advertisment
Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:160

Official publication of the Indian Society of Nephrology
 ~   Next article
 ~   Previous article
 ~   Table of Contents

 ~   Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~Related articles
 ~   Citation Manager
 ~   Access Statistics
 ~   Reader Comments
 ~   Email Alert *
 ~   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3446    
    Printed156    
    Emailed1    
    PDF Downloaded221    
    Comments [Add]    
    Cited by others 3    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2012  |  Volume : 22  |  Issue : 3  |  Page : 168-173

Effect of short-term intravenous ascorbic acid on reducing ferritin in hemodialysis patients


1 Department of Nephrology, Imam Hossein Hospital, Tehran, Iran
2 Department of Internal Medicine, Vali-asr Hospital of Zanjan University of Medical Sciences, Zanjan, Iran
3 Student Research Committee, Vali-asr Hospital of Zanjan University of Medical Sciences, Zanjan, Iran
4 Department of Nephrology, Taleghani Hospital of Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence Address:
M H Ghadiani
Department of Nephrology, Shahid Beheshti University of Medical Sciences, Tehran
Iran
Login to access the Email id

Source of Support: Iranís Zanjan University of Medical Sciences, Conflict of Interest: None


DOI: 10.4103/0971-4065.86407

Rights and Permissions

Resistance to recombinant erythropoietin (rEPO) in hemodialysis patients may be due to inadequate iron recruitment and defect in iron use. In this cross over randomized clinical trial, 30 hemodialysis patients with serum ferritin levels of ≥500 ng/ml, hemoglobin ≤11.0 g/dl, and transferrin saturation (TSAT) of 20% or less were administrated intravenous iron (50-100 mg/wk) and rEPO (120-360 U/kg/wk) for 6 months. Patients were excluded if there was a clear explanation for rEPO hyporesponsiveness. Patients were divided into two groups. Group1 received standard care and 500 mg of intravenous ascorbic acid (IVAA) with each dialysis session in the first week of each month for a total of 3 months. Group 2 received standard care only. After 2 month washout period, groups were crossed over. Each month hemoglobin (Hb) was assessed. Iron, TIBC (transferrin iron binding capacity), TSAT, iPTH (intact parathyroid hormone), liver enzymes, albumin and cholesterol levels were measured every 3 months. After 3 months of intervention, Hb significantly increased from 10.11 to 12.19 g/dl (P <0 0.001; 95% confidence interval [CI] 2.7-1.4) and TSAT increased from 18.9 to 28.1% (P = 0.008; 95% CI 0.09-3), while ferritin and serum iron declined significantly from 1391 to 938 ng/ml (P = 0.001; 95% CI 216-689), 97.2 to 64.6 (P = 0.001; 95% CI 14.8-50.4) in the study group. Change of Hb over time in IVAA group was significant (P < 0.0005). There were significant differences between two groups in change of Hb level over time (P < 0.0005) and treatment effect (P = 0.002). Baseline laboratory tests were similar in the two groups and there was no carry over effect at phase 2. We showed that low amount of IVAA could reduce ferritin level and enhance Hb and TSAT, suggesting improved iron utilization.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

© Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07